Research Article| Volume 19, ISSUE 3, P582-602, May 1997

Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization

      This paper is only available as a PDF. To read, Please Download here.


      From January 1994 through May 1995, Prudential HealthCare—North Texas prospectively studied 299 member patients diagnosed with hypercholesterolemia for whom pharmacotherapy with one of four 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, also known as statins, was prescribed. The purpose of this study was to measure the relative cost-effectiveness (CE) of these drugs in a real-world setting. This study provides information to assist decision makers in managed-care organizations (MCO) in making formulary selections. The study used a prospective, randomized, balanced cohort design, examining patients who had been prescribed initial therapy with a statin drug as monotherapy. Costs (direct medical and indirect costs) and effectiveness (percent reduction in low-density lipoprotein cholesterol levels) were based on approximately the first 6 months of initial therapy. Both the MCO and patient perspectives were considered. In the base case, mean CE ratios were significantly lower for fluvastatin compared with lovastatin, pravastatin, and simvastatin from both the managed-care perspective and the patient perspective. Sensitivity analysis did not alter the CE conclusions, even under conditions of varying cost structures. Although differences were found in the effectiveness of lovastatin, pravastatin, and simvastatin measured in this study versus efficacy measured for these drugs in controlled clinical trials, sensitivity analysis suggests that these differences alone do not determine the superior CE of fluvastatin. Finally, this study supports the idea that well-designed formularies should consider drug CE (based on safety, effectiveness, and cost) and that integration of the pharmacy benefit management with other medical management is essential. These results provide evidence that fluvastatin may represent a more cost-effective formulary choice among statin products used for initial monotherapy of hypercholesterolemia.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kannel WB
        • Castelli WP
        • Gordon T
        • McNamara PM
        Serum cholesterol, lipoproteins, and the risk of coronary heart disease.
        Ann Intern Med. 1971; 74: 1-12
        • Martin MJ
        • Hulley SB
        • Browner WS
        • et al.
        Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,622 men.
        Lancet. 1986; 2: 933-939
        • Rose G
        • Shipley M
        Plasma cholesterol concentration and death from coronary disease: 10 year results of the Whitehall Study.
        BMJ. 1986; 293: 306-307
        • Goldbourt U
        • Yaari S
        Cholesterol and coronary heart disease mortality: A 23-year follow-up study of 9902 men in Israel.
        Arteriosclerosis. 1990; 10: 512-519
        • Pekkanen J
        • Nissinen A
        • Punsar S
        • Karvonen MJ
        Short- and long-term association of serum cholesterol with mortality: The 25-year follow-up of the Finnish cohorts of the seven countries study.
        Am J Epidemiol. 1992; 135: 1251-1258
        • Benfante R
        • Reed D
        Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly?.
        JAMA. 1990; 263: 393-396
        • Aronow WS
        • Ahn C
        Correlation of serum lipids with the presence or absence of coronary artery disease in 1793 men and women aged ≥ 62 years.
        Am J Cardiol. 1994; 73: 702-703
        • Isles CG
        • Hole DJ
        • Gillis CR
        • et al.
        Plasma cholesterol, coronary heart disease, and cancer in the Renfrow and Paisley survey.
        BMJ. 1989; 298: 920-924
        • Neaton JD
        • Kuller LH
        • Wentworth D
        • Borhani NO
        Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentrations, and diastolic blood pressure among black and white males followed for five years.
        Am Heart J. 1984; 108: 759-769
        • Lipid Research Clinics Program
        The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.
        JAMA. 1984; 253: 2080-2086
        • Carlson LA
        • Rosenhamer G
        Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.
        Acta Med Scand. 1988; 223: 405-418
        • ATP II Panel
        Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
        JAMA. 1993; 269: 3015-3023
        • Schuler G
        • Hanbredt R
        • Schlierf G
        • et al.
        Regular physical exercise and low-fat diet: Effects on progression of coronary artery disease.
        Circulation. 1992; 86: 1-11
        • Brensike JF
        • Levy RI
        • Kelsey SF
        • et al.
        Effects of therapy with cholestyramine on progression of coronary atherosclerosis: Results of the NHLBI type II coronary intervention study.
        Circulation. 1984; 69: 313-324
        • Blankenhorn DH
        • Nessim SA
        • Johnson RD
        • et al.
        Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
        JAMA. 1987; 257: 3233-3240
        • Alderman EL
        • Haskell WL
        • Fair JM
        • et al.
        Beneficial angiographic and clinical response to multifactor modification in the Stanford Coronary Risk Intervention Project (SCRIP).
        Circulation. 1994; 89: 975-990
        • The Scandinavian Simvastatin Survival Study Group
        Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Slater EE
        • MacDonald JS
        Mechanism of action and biological profile of HMG-CoA reductase inhibitors: A new therapeutic alternative.
        Drugs. 1988; 36 (Suppl 3): 72-82
        • Grundy SM
        HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.
        NEJM. 1988; 319: 24-33
        • Davidson MH
        Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety.
        Am J Med. 1994; 96 (Suppl 6A): 6A 415-6A 445
        • Bradford RH
        • Shear CL
        • Athanassios NC
        • et al.
        Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia.
        Arch Intern Med. 1991; 151: 43-49
        • Behounek BD
        • McGovern ME
        • Kessler-Taub KB
        • et al.
        Effects of pravastatin in patients with serum cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dL) plus two additional atherosclerotic risk factors.
        Am J Cardiol. 1993; 72: 1031-1037
        • Farmer JA
        • Washington LC
        • Jones PH
        • et al.
        Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia.
        Clin Ther. 1992; 14: 708-717
        • Andrade SE
        • Walker AM
        • Gottlieb LK
        • et al.
        Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings?.
        NEJM. 1995; 332: 1125-1131
        • Hsu I
        • Spinler SA
        • Johnson NE
        Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
        Ann Pharmacother. 1995; 29: 743-759
        • Havel RJ
        • Rapaport E
        Management of primary hyperlipidemia.
        NEJM. 1995; 332: 1491-1498
        • Schulman KA
        • Kinosian B
        • Jacobson TA
        • et al.
        Reducing high blood cholesterol level with drugs: Cost-effectiveness of pharmacological management.
        JAMA. 1990; 264: 3025-3033
        • Goldman L
        • Weinstein MC
        • Goldman PA
        • Williams LW
        Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
        JAMA. 1991; 265: 1145-1151
        • Hay JW
        • Wittels EH
        • Gotto AM
        An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction.
        Am J Cardiol. 1991; 67: 789-792
        • Martens LL
        • Guibert R
        Cost-effectiveness analysis of lipid-modifying therapy in Canada: Comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
        Clin Ther. 1994; 16: 1052-1067
        • Korman L
        • Borysiuk L
        Replacing lovastatin with pravastatin: Effect on serum lipids and costs.
        Am J Health Syst Pharm. 1995; 52: 1078-1082
        • Blum CB
        Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
        Am J Cardiol. 1994; 73 (Suppl): 3D-11D
        • Zar JH
        Single factor analysis of variance by ranks.
        in: Biostatistical Analysis. Prentice-Hall, Inc, Englewood Cliffs, NJ1974: 139-142
        • Zar JH
        Confidence intervals for differences between means.
        in: Biostatistical Analysis. Prentice Hall, Inc, Englewood Cliffs, NJ1974: 155-156
        • Larson LN
        Cost determination and analysis.
        in: Bootman JL Townsend RJ McGhan WF Principles of Pharmacoeconomics. Harvey Whitney Books, New York1994: 35-49
        • Drummond MF
        • Stoddart GL
        • Torrance GW
        Critical assessment of economic evaluation.
        in: House J Methods for the Economic Evaluation of Health Care Programmers. Oxford University Press, New York1994: 26-27
        • Task Force on Principles for Economic Analysis of Health Care Technology
        Economic analysis of health care technology: A report of principles.
        Ann Intern Med. 1995; 122: 61-70
        • Guyatt G
        • Drummond M
        • Feeny D
        • et al.
        Guidelines for the clinical and economic evaluation of health care technologies.
        Soc Sci Med. 1986; 22: 393-408
        • Chrischilles EA
        Cost-effectiveness analysis.
        in: Bootman JL Townsend RJ McGhan WF Principles of Pharmacoeconomics. Harvey Whitney Books, New York1991: 72-101
      1. Krischner CG Burkett RC Kotowicz GM Physicians' Current Procedural Terminology (CPT 1995). American Medical Association, Chicago, Ill1994
      2. Medical Prevailing Healthcare Charges System. Health Insurance Association of America, Washington, DC1995
        • US Department of Labor
        Vital Statistics, 1994. Bureau of Labor Statistics, Washington, DC1994
        • Rovira J
        • Antonanzas F
        Economic analysis of health technologies and programmes: A Spanish proposal for methodological standardization.
        PharmacoEconomics. 1995; 8: 245-252
        • Sacristan J
        • Simon JD
        • Navarro O
        • et al.
        Use of confidence intervals and sample size calculations in health economic studies.
        Ann Pharmacother. 1995; 29: 719-724
        • Epstein RS
        • Garrahan S
        • Nelsen L
        • et al.
        The cholesterol population model: US population requirements for treatment of hypercholesterolemia.
        Am J Managed Care. 1996; 2: 1362-1370
        • Zovoral JH
        • Haggerty BJ
        • Winick AG
        • Bergmann SD
        Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
        Am J Cardiol. 1995; 76 (FLUENT Study Group) (Suppl 2): 37A-40A
        • Baggio G
        • DeCandia O
        • Forte PL
        Efficacy and safety of fluvastatin, a new HMG-CoA reductase inhibitor, in elderly hypercholesterolemic women.
        Drugs. 1994; 47 (Suppl): 59-63
        • Dallongevvile J
        • Fruchant J-C
        • Pfister P
        • Bard J-M
        Fluvastatin reduces levels of plasma apo B-containing particles and increases those of Lp(a)-1.
        Am J Med. 1994; 96 (European Fluvastatin Study Group) (Suppl): 325-365
        • McPherson R
        • Bedford J
        • Connally P
        • et al.
        Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
        Clin Ther. 1992; 14: 276-291
        • Stalenhoef AF
        • Lansberg PJ
        • Kroon AA
        • et al.
        Treatment of primary hypercholesterolemia: Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: A double-blind comparative study.
        J Intern Med. 1993; 234: 77-82
        • Tronulefro J
        • Guinaracas AC
        • Kettoer H
        • et al.
        Dose-response of simvastatin in primary hypercholesterolemia.
        J Cardiovasc Pharmacol. 1994; 24: 941-949
        • Salonen R
        • Kristijna N
        • Porkkala E
        A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.
        Circulation. 1995; 92 (Kupio Atherosclerosis Prevention Study (KAPS)): 1758-1764